表 1.

ICI对BRAF突变的NSCLC的疗效

Efficacy of ICIs for BRAF-mutated NSCLC

Study	Year	Mutation	Subtype	Treatment	ICI line	Total No.	ORR	DCR	mPFS (mon)	mOS (mon)
ICIs: immune check point inhibitors; NSCLC: non-small cell lung cancer; PD-1: programmed cell death receptor-1; PD-L1: PD ligand 1; ORR: objective response rate; mPFS: median progression-free survival; mOS: median overall survival; DCR: disease control rate; NR: not reported.
Dudnik, et al[10]	2018	BRAF	V600E	PD-(L)1 mAb	2	4	25%	-	1.5	NR
	2018	BRAF	nonV600E	PD-(L)1 mAb	2	5	20%	-	2.6	NR
Mazieres, et al[13]	2019	BRAF	NA	94% PD-1 mAb	3	43	24%	54%	3.1	13.6
Rihawi, et al[14]	2019	BRAF	NA	PD-1 mAb	2	11	9%	-	-	10.3
Guisier, et al[16]	2020	BRAF	V600E	PD-(L)1 mAb	2	26	26%	61%	5.3	22.5
	2020	BRAF	nonV600E	PD-(L)1 mAb	2	18	35%	53%	4.9	12.0
Dudnik, et al[17]	2018	BRAF	V600E	95% PD-1 mAb	2	12	25%	50%	3.7	NR
	2018	BRAF	nonV600E	95% PD-1 mAb	2	10	33%	56%	4.1	NR